Filing Flows › GoodRx Holdings (GDRX) › R&D spending
GoodRx Holdings (GDRX) R&D spending by quarter
GoodRx Holdings' R&D spending was $26.7M in Q2 2026 (second quarter 2026), -11% from Q1 2026. Over the last 7 quarters it ranged from $26.7M (Q2 2026) to $31.7M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $26.7M | -11% | -11% |
| Q1 2026 | $30.2M | +4% | -3% |
| Q4 2025 | $28.9M | -7% | -9% |
| Q3 2025 | $31.0M | +4% | — |
| Q2 2025 | $29.9M | -4% | — |
| Q1 2025 | $31.1M | -2% | — |
| Q4 2024 | $31.7M | — | — |
Q2 2026 at a glance
GoodRx Holdings, Q2 2026: revenue $200M (-1% year over year), operating margin 11.8%, net earnings $8.5M, operating cash flow $80.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is GoodRx Holdings' R&D spending?
GoodRx Holdings' R&D spending was $26.7M in Q2 2026 (second quarter 2026), -11% from Q1 2026.
How has GoodRx Holdings' R&D spending changed?
Over the last 7 quarters it ranged from $26.7M (Q2 2026) to $31.7M (Q4 2024).